An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes
An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes is a paper indexed in ScholarIQ from OpenAlex.
How many citations does An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes have?
An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes has 1,141 citations in the OpenAlex counts ScholarIQ stores.
When was An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes published?
An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes has 2019 year in the ScholarIQ index.
What is the open-access status of An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes?
An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes has bronze oa status in the ScholarIQ index.
What is the DOI of An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes?
The DOI for An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes is on the source record.
What is the PMID of An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes?
The PMID for An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes is on the source record.
What is the OpenAlex record for An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes?
The OpenAlex for An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes is on the source record.